Multivariate Biomarker Panel for Predicting MS Disease Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for predicting multiple sclerosis (MS) disease activity are limited by low sensitivity, inability to distinguish subtle disease activity, and lack of specificity, particularly in differentiating MS from other neurological conditions.
Innovation Solution
A multivariate biomarker panel comprising specific biomarkers (e.g., NEFL, MOG, CXCL9, OPG, OPN, CXCL13, GFAP) is used to generate predictions of MS disease activity through a predictive model, improving sensitivity and specificity by incorporating shifts in biomarker levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If individual biomarkers are used to detect MS disease activity, then the testing process is simple, but the sensitivity and predictive power are low
Solution Approach 1:
The patent combines multiple individual biomarkers into a unified multivariate biomarker panel that simultaneously measures several biomarkers (such as neurofilament light chain, GFAP, myelin oligodendrocyte glycoprotein, and inflammatory cytokines) to collectively predict MS disease activity. This merging approach improves sensitivity and predictive power while maintaining clinical utility through integrated analysis
2Reliability
If individual biomarkers are used, then the test is easier to perform, but the ability to differentiate MS-specific disease activity from other neurological conditions is poor
Solution Approach 1:
The patent assigns different functional roles to specific biomarkers within the panel: neurodegeneration biomarkers (neurofilament light chain, GFAP) detect tissue damage, myelin-specific biomarkers (MOG) identify MS-specific pathology, and inflammatory biomarkers (cytokines) indicate active inflammation. This local differentiation of biomarker functions enables specific identification of MS disease activity patterns distinct from other neurological conditions
3Reliability
If individual biomarkers are used to predict lesion progression, then the methodology is straightforward, but the predictive power is insufficient
Solution Approach 1:
The patent implements a predictive model that incorporates temporal dynamics by analyzing changes in biomarker levels over time. The model uses baseline biomarker concentrations and their subsequent changes to predict future disease activity and lesion progression, providing feedback that guides clinical decision-making and treatment adjustments
Data Source
AI summary
Disclosed herein are methods for analyzing quantitative expression values of biomarkers of a biomarker panel for determining disease activity in a human subject. Further disclosed herein are kits for measuring quantitative expression values of the markers as well as computer systems and software embodiments of predictive models for determining disease activity in human subjects based on the quantitative expression values of the markers.